| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.
We dont just treat cancer, we treat people. You can count on us to put you first and provide the most advanced treatments. Lets beat this together.
Micron Technologies is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TheraTrue prides itself on its commitment to operating fully regulated, transparent, and highly professional facilities that will deliver vital products to improve the quality of life for patients suffering from debilitating medical conditions.